查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1758765

全球液体切片检查市场

Fluid Biopsy
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 282 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球液体切片检查市场规模将达到 210 亿美元

全球液体切片检查市场规模预计在2024年为114亿美元，到2030年将达到210亿美元，在分析期间（2024-2030年）的复合年增长率为10.6%。作为本报告分析的细分市场之一，肺癌市场预计将以12.4%的复合年增长率成长，到分析期结束时达到82亿美元。乳癌市场在分析期间内的复合年增长率预计为8.3%。

美国市场规模估计为 31 亿美元，中国市场预计复合年增长率为 14.7%

美国液体切片检查市场规模预计2024年达到31亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到44亿美元，在2024-2030年的分析期间内，复合年增长率为14.7%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为7.5%和9.5%。在欧洲，预计德国市场的复合年增长率约为8.4%。

全球液体切片检查市场－主要趋势和驱动因素摘要

为什么液体切片切片检查会成为癌症诊断领域的颠覆性力量？

液体切片检查（又称液态切片）正在改变癌症诊断和疾病监测，它提供了一种非侵入性的传统组织切片检查替代方法。液体切片检查透过分析来自生物体液（主要是血液）的肿瘤衍生成分，例如循环肿瘤DNA (ctDNA)、循环性肿瘤细胞(CTC)、外泌体和微型RNA ，实现早期癌症检测、即时疾病追踪和治疗反应评估。它无需手术取样即可捕捉肿瘤异质性，这使得它在转移性肿瘤和难以接近的肿瘤环境中尤其有价值。

这种方法因其在检测微量残存疾病(MRD)、识别可操作突变以及指南多种癌症（包括肺癌、乳癌、结直肠癌和前列腺癌等）的个性化治疗决策方面的潜力，在肿瘤学领域获得了广泛关注。与可能受操作风险和空间限制的组织切片检查不同，液体切片检查允许在病程中反覆取样。随着精准医疗的不断发展，液体切片检查正成为动态肿瘤分析和治疗调整的重要工具。

哪些技术进步正在扩大液体切片检查的可能性？

分子生物学、基因组定序和数位PCR技术的进步极大地提高了液体切片检查的准确性和临床效用。次世代定序（NGS）平台如今能够高灵敏度地检测ctDNA中的低频突变，从而能够早期识别肿瘤相关的基因组变异。液滴数位PCR（ddPCR）和BEAMing（磁珠法、乳化法、扩增法、磁力法）正被用于定量突变，从而能够纵向追踪肿瘤的严重和治疗反应。

基于微流体的平台和CTC富集技术正在提高从血液样本中捕获稀有细胞和颗粒的效率。同时，人工智慧主导的数据解读工具正在促进复杂分子特征的快速分析，以支援即时临床决策。尿液、脑脊髓液和唾液等多种体液类型生物标记的多重分析和整合方面的进展，正在将液体切片检查的应用范围从肿瘤学扩展到产前筛检、器官移植监测和感染疾病监测等其他领域。

哪些临床/治疗领域越来越多地采用液体切片检查？

液体切片检查主要用于肿瘤学，以支持早期癌症筛检、伴随诊断和抗药性突变检测。例如，在非小细胞肺癌 (NSCLC) 中，液体切片检查通常用于检测 EGFR 突变并指导标靶治疗。乳癌和摄护腺癌也是重要的研究领域，在这些领域中，连续液体切片检查有助于监测荷尔蒙受体状态和转移进展，而无需重复影像学检查或手术。

除了固体癌外，骨髓恶性肿瘤也开始受益于基于ctDNA的微量残存疾病检测，尤其是在白血病和淋巴瘤。临床试验通常结合液体切片检查终点来分层患者、评估药物疗效，并将分子反应与临床结果关联。同时，液体活检在免疫肿瘤学中的应用也在不断扩展，研究人员正在使用液体切片检查来评估肿瘤突变负荷(TMB)并预测对查核点抑制剂的疗效。液体切片检查的多功能性和扩充性使其在人群筛检倡议和照护现场诊断框架中广泛应用。

支持液体切片检查市场成长的关键驱动因素有哪些？

液体切片检查市场的成长受到多种因素的共同驱动，这些因素根植于临床效用、技术成熟度以及医疗保健系统的需求。主要驱动因素是对非侵入性、患者友善诊断工具日益增长的需求，这些工具可以减少手术相关併发症并实现频繁的疾病监测。这符合全球对个人化医疗、早期疗育和基于结果的治疗模式的青睐趋势。

随着低成本先进定序技术的出现，液体切片检查正日益普及，临床医生和诊断实验室都能够轻鬆应用。全球癌症发生率的上升，加上对及时分子决策支援的需求，正加速其在临床上的应用。基于液态切片的伴随诊断已获得监管机构的核准，主要市场也开始提供报销支持，这进一步巩固了液态切片在标准肿瘤学工作流程中的地位。此外，精准肿瘤学研究、生物製药合作以及新兴企业创新的强劲投资，正在催生一个充满活力且竞争激烈的生态系统，不断拓展液体切片检查应用的前沿领域。这些因素共同作用，使液体切片检查成为未来疾病检测和个人化治疗的颠覆性技术。

部分

适应症（肺癌、乳癌、结肠癌、其他适应症）；模式种（循环性肿瘤细胞、循环肿瘤DNA、游离DNA）

受访公司范例（总合42家公司）

  • Angle plc
  • Biocept, Inc.
  • Bio-Rad Laboratories, Inc.
  • Caris Life Sciences
  • CellMax Life
  • Cynvenio Biosystems, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Freenome Holdings, Inc.
  • GRAIL, Inc.
  • Guardant Health, Inc.
  • Helio Health
  • Illumina, Inc.
  • Inivata Ltd
  • Invitae Corporation
  • Lucence Diagnostics Pte Ltd
  • Menarini Silicon Biosystems
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories
  • QIAGEN NV
  • Resolution Bioscience（Agilent）
  • Sysmex Corporation
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.

人工智慧集成

我们正在利用可操作的专家内容和人工智慧工具来改变市场和竞争情报。

Global 特定产业SLM 的典型规范，而是建立了一个从全球专家收集的内容库，其中包括视讯录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况（成品和原始OEM）预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP36918

Global Fluid Biopsy Market to Reach US$21.0 Billion by 2030

The global market for Fluid Biopsy estimated at US$11.4 Billion in the year 2024, is expected to reach US$21.0 Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2024-2030. Lung Cancer, one of the segments analyzed in the report, is expected to record a 12.4% CAGR and reach US$8.2 Billion by the end of the analysis period. Growth in the Breast Cancer segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.1 Billion While China is Forecast to Grow at 14.7% CAGR

The Fluid Biopsy market in the U.S. is estimated at US$3.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2030 trailing a CAGR of 14.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 9.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Global Fluid Biopsy Market - Key Trends & Drivers Summarized

Why Is Fluid Biopsy Emerging as a Disruptive Force in Cancer Diagnostics?

Fluid biopsy-also known as liquid biopsy-is transforming cancer diagnostics and disease monitoring by offering a non-invasive alternative to traditional tissue biopsies. By analyzing tumor-derived components such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and microRNAs from biological fluids (mainly blood), fluid biopsy enables early cancer detection, real-time disease tracking, and therapeutic response assessment. Its ability to capture tumor heterogeneity without the need for surgical sampling is particularly valuable in metastatic and inaccessible tumor settings.

This approach is gaining prominence in oncology due to its potential for detecting minimal residual disease (MRD), identifying actionable mutations, and guiding personalized therapy decisions across various cancer types-particularly lung, breast, colorectal, and prostate cancers. Unlike tissue biopsies that may be limited by procedural risks and spatial constraints, fluid biopsy allows for repeatable sampling over the disease course. As precision medicine continues to evolve, fluid biopsy is becoming an essential tool for dynamic tumor profiling and treatment adjustment.

What Technological Innovations Are Expanding the Potential of Fluid Biopsies?

Technological advancements in molecular biology, genomic sequencing, and digital PCR have significantly expanded the accuracy and clinical utility of fluid biopsies. Next-generation sequencing (NGS) platforms can now detect low-frequency mutations in ctDNA with high sensitivity, enabling early identification of tumor-related genomic alterations. Droplet digital PCR (ddPCR) and BEAMing (Beads, Emulsion, Amplification, Magnetics) are being utilized for mutation quantification, allowing for longitudinal tracking of tumor burden and therapy response.

Microfluidics-based platforms and CTC enrichment technologies are improving the capture efficiency of rare cells and particles from blood samples. Simultaneously, AI-driven data interpretation tools are facilitating rapid analysis of complex molecular signatures, supporting real-time clinical decision-making. Advances in multiplexing and integration of biomarkers from multiple fluid types-including urine, cerebrospinal fluid, and saliva-are extending fluid biopsy’s applications beyond oncology into other domains such as prenatal screening, organ transplant monitoring, and infectious disease surveillance.

Which Clinical and Therapeutic Areas Are Accelerating Adoption of Fluid Biopsy?

Fluid biopsy is primarily utilized in oncology, where it supports early cancer screening, companion diagnostics, and resistance mutation detection. In non-small cell lung cancer (NSCLC), for example, fluid biopsy is routinely used to detect EGFR mutations and guide the use of targeted therapies. Breast and prostate cancers are also key areas where serial fluid biopsies help monitor hormone receptor status and metastatic progression without repeated imaging or surgery.

Beyond solid tumors, hematological malignancies are beginning to benefit from ctDNA-based minimal residual disease detection, particularly in leukemias and lymphomas. Clinical trials now commonly incorporate fluid biopsy endpoints to stratify patients, evaluate drug efficacy, and correlate molecular response with clinical outcomes. Meanwhile, its application in immuno-oncology is expanding as researchers use fluid biopsy to assess tumor mutational burden (TMB) and predict response to checkpoint inhibitors. The versatility and scalability of fluid biopsy are also enabling broader adoption in population screening initiatives and point-of-care diagnostic frameworks.

What Are the Main Drivers Supporting Growth in the Fluid Biopsy Market?

The growth in the fluid biopsy market is driven by several converging factors rooted in clinical utility, technological maturity, and healthcare system needs. A primary driver is the growing demand for non-invasive, patient-friendly diagnostic tools that reduce procedure-related complications and enable frequent disease monitoring. This aligns with global trends favoring personalized medicine, early intervention, and outcomes-based treatment models.

The increasing availability of advanced sequencing technologies at lower costs is making fluid biopsy more accessible to both clinicians and diagnostic laboratories. Rising cancer incidence worldwide, combined with the need for timely, molecular-level decision support, is accelerating clinical adoption. Regulatory approvals for liquid biopsy-based companion diagnostics and reimbursement support in key markets are further solidifying its role in standard oncology workflows. Additionally, robust investments in precision oncology research, biopharma collaborations, and startup innovation are fueling a dynamic and competitive ecosystem that continues to expand the frontiers of fluid biopsy applications. Collectively, these drivers position fluid biopsy as a transformative force in the future of disease detection and personalized treatment.

SCOPE OF STUDY:

The report analyzes the Fluid Biopsy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Other Indications); Type (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Angle plc
  • Biocept, Inc.
  • Bio-Rad Laboratories, Inc.
  • Caris Life Sciences
  • CellMax Life
  • Cynvenio Biosystems, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Freenome Holdings, Inc.
  • GRAIL, Inc.
  • Guardant Health, Inc.
  • Helio Health
  • Illumina, Inc.
  • Inivata Ltd
  • Invitae Corporation
  • Lucence Diagnostics Pte Ltd
  • Menarini Silicon Biosystems
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories
  • QIAGEN N.V.
  • Resolution Bioscience (Agilent)
  • Sysmex Corporation
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Fluid Biopsy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Cancer Throws the Spotlight on Non-Invasive Diagnostic Technologies
    • Growing Clinical Focus on Real-Time Tumor Monitoring Drives Demand for Liquid Biopsy Platforms
    • Technological Advancements in Circulating Biomarker Detection Accelerate Market Expansion
    • Expansion of Precision Medicine Programs Strengthens Business Case for Fluid Biopsy Applications
    • Integration of Multi-Omics Approaches Spurs Innovation in Personalized Cancer Diagnostics
    • Increase in Pharmaceutical R&D Pipelines Boosts Utility of Fluid Biopsy in Clinical Trials
    • Emergence of cfDNA and CTC-Based Panels Expands Diagnostic Utility Beyond Oncology
    • Surge in Patient Preference for Less Invasive Procedures Generates Growth Opportunities
    • AI-Powered Data Analysis Tools Improve Accuracy and Interpretation of Fluid Biopsy Results
    • Growth in Early Cancer Screening Initiatives Drives Adoption of Blood-Based Biopsy Platforms
    • Advances in Microfluidics and NGS Technologies Enhance Sensitivity of Fluid Biopsy Systems
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Fluid Biopsy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Fluid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Fluid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Fluid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Circulating Tumor Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Circulating Tumor Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Circulating Tumor Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Circulating Tumor DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Circulating Tumor DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Circulating Tumor DNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cell-Free DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cell-Free DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Cell-Free DNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • JAPAN
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • CHINA
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • EUROPE
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Fluid Biopsy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Fluid Biopsy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Fluid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • FRANCE
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • GERMANY
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Fluid Biopsy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Fluid Biopsy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Fluid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • INDIA
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Fluid Biopsy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Fluid Biopsy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Fluid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Fluid Biopsy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Fluid Biopsy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Fluid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030
  • AFRICA
    • Fluid Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Fluid Biopsy by Indication - Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Fluid Biopsy by Indication - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Colorectal Cancer and Other Indications for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Fluid Biopsy by Type - Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Fluid Biopsy by Type - Percentage Breakdown of Value Sales for Circulating Tumor Cells, Circulating Tumor DNA and Cell-Free DNA for the Years 2014, 2025 & 2030

IV. COMPETITION